DIPG-53. Long-term survival from a Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic(124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG).

BACKGROUND: Median survival from DIPG is less than one year. In a phase 1 dose escalation study (clinicaltrials.gov NCT01502917) (124)I-omburtamab targeting B7-H3 was administered intratumorally using CED. METHODS: CED was performed between 4-14 weeks post radiation therapy. Using a 3 + 3 design, (1...

Descripción completa

Detalles Bibliográficos
Autores principales: Souweidane, Mark M, Kramer, Kim, Pandit-Tasker, Neeta, Haque, Sofia, Zanzonico, Pat, Carrasquillo, Jorge, Lyashchenko, Serge K, Thakur, Sunitha B, Khakoo, Yasmin, Dunkel, Ira J, Donzelli, Maria, Lewis, Jason S, Cheung, Nai-Kong V, Larson, Steve M, Reiner, Anne S, Panageas, Katherine S, Manino, Nicole, Nielsen, John Rømer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Diffuse Midline Glioma/DIPG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165135/
http://dx.doi.org/10.1093/neuonc/noac079.110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165135/
http://dx.doi.org/10.1093/neuonc/noac079.110

Ejemplares similares